ATE471147T1 - Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren - Google Patents

Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren

Info

Publication number
ATE471147T1
ATE471147T1 AT05769799T AT05769799T ATE471147T1 AT E471147 T1 ATE471147 T1 AT E471147T1 AT 05769799 T AT05769799 T AT 05769799T AT 05769799 T AT05769799 T AT 05769799T AT E471147 T1 ATE471147 T1 AT E471147T1
Authority
AT
Austria
Prior art keywords
halobenzyloxy
propanamides
benzylamino
sodium
calcium channel
Prior art date
Application number
AT05769799T
Other languages
English (en)
Inventor
Elena Barbanti
Florian Thaler
Carla Caccia
Ruggero Fariello
Patricia Salvati
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Application granted granted Critical
Publication of ATE471147T1 publication Critical patent/ATE471147T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05769799T 2004-09-10 2005-07-28 Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren ATE471147T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04021525 2004-09-10
PCT/EP2005/008200 WO2006027052A2 (en) 2004-09-10 2005-07-28 (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators

Publications (1)

Publication Number Publication Date
ATE471147T1 true ATE471147T1 (de) 2010-07-15

Family

ID=34926488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05769799T ATE471147T1 (de) 2004-09-10 2005-07-28 Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren

Country Status (28)

Country Link
US (2) US20080096965A1 (de)
EP (1) EP1809271B9 (de)
JP (1) JP5319920B2 (de)
KR (1) KR101277520B1 (de)
CN (1) CN101018546B (de)
AR (1) AR050638A1 (de)
AT (1) ATE471147T1 (de)
AU (1) AU2005282028B2 (de)
BR (1) BRPI0515154A (de)
CA (1) CA2577408C (de)
CY (1) CY1110770T1 (de)
DE (1) DE602005021907D1 (de)
DK (1) DK1809271T5 (de)
ES (1) ES2347581T3 (de)
HK (1) HK1105359A1 (de)
HR (1) HRP20100400T1 (de)
IL (1) IL181445A (de)
ME (1) ME01801B (de)
MX (1) MX2007002713A (de)
NO (1) NO338713B1 (de)
NZ (1) NZ553970A (de)
PL (1) PL1809271T3 (de)
PT (1) PT1809271E (de)
RS (1) RS51411B (de)
RU (1) RU2391973C2 (de)
SI (1) SI1809271T1 (de)
TW (1) TWI351950B (de)
WO (1) WO2006027052A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002009A (es) * 2001-09-03 2004-07-08 Newron Pharm Spa Composicion farmaceutica que comprende gabapentina o un analogo de la misma y alfa-aminoamida y su uso como analgesico.
EP1438956A1 (de) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-Aminoamidderivate die als Antimigränemittel nützlich sind
CA2536764C (en) * 2003-08-25 2013-09-17 Newron Pharmaceuticals, S.P.A. .alpha.-aminoamide derivatives useful as anti-inflammatory agents
KR101277520B1 (ko) * 2004-09-10 2013-06-21 뉴론 파마슈티칼즈 에스. 피. 에이. （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물
ES2556937T3 (es) 2005-12-22 2016-01-21 Newron Pharmaceuticals S.P.A. Derivados de 2-feniletilamino como moduladores de los canales de calcio y/o sodio
CN101472880B (zh) * 2006-06-19 2013-04-24 纽朗制药有限公司 生产2-[4-(3-和2-氟苄氧基)苄氨基]丙酰胺类的方法
SI2155663T1 (en) 2007-06-15 2018-03-30 Newron Pharmaceuticals S.P.A. SUBSTITUTED 2- (2- (PHENYL) ETHYLAMINO) ALKANAMIDIC DERIVATIVES AND THEIR USE AS SODIUM AND / OR CALCIUM CHANNEL MODULATORS
ES2837000T3 (es) * 2007-12-11 2021-06-29 Newron Pharm Spa Uso terapéutico de 2-[4-(3- o 2-fluorobenciloxi)bencilamino]propanamidas con alto grado de pureza
CA2707646C (en) * 2007-12-19 2016-09-13 Newron Pharmaceuticals S.P.A. Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009109334A1 (en) * 2008-03-07 2009-09-11 Newron Pharmaceuticals S.P.A. (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
US9549967B2 (en) 2009-05-29 2017-01-24 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
CN105037188B (zh) * 2010-04-27 2017-06-23 纽朗制药有限公司 用于制备拉非酰胺甲磺酸盐或其r‑对映异构体的方法
HUE030031T2 (en) 2011-06-27 2017-04-28 Newron Pharm Spa Fluorinated arylalkylaminocarboxamide derivatives
JP2017536334A (ja) 2014-10-08 2017-12-07 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ナトリウムチャネルの改善されたペプチド阻害剤
MX2019012635A (es) * 2017-06-20 2019-12-11 Raqualia Pharma Inc Derivados de amida como bloqueadores de nav1.7 y nav1.8.

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3451062A (en) * 1966-03-16 1969-06-24 Theodore Bradley Disposable examination gown
US3658967A (en) * 1966-06-23 1972-04-25 Ici Ltd Carboxylic acid derivatives for lowering the concentration of triglycerides in the blood
GB1140748A (en) * 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
CH480308A (de) * 1966-08-11 1969-10-31 Ciba Geigy Verfahren zur Herstellung von Thiosemicarbazid-Verbindungen
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4311853A (en) * 1979-02-06 1982-01-19 The Radiochemical Centre Limited Selenium derivatives of thyroxine and tri-iodothyronine
DE3050800C2 (de) * 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be
US4267354A (en) * 1979-04-25 1981-05-12 E. R. Squibb & Sons, Inc. Substituted amides having antiinflammatory activity and intermediates
AU530999B2 (en) * 1979-06-01 1983-08-04 Wellcome Foundation Limited, The Substituted amino triazines and their use in treatment of cns disorders
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
EP0144853B1 (de) * 1983-11-21 1990-09-26 Fujisawa Pharmaceutical Co., Ltd. Semicarbazid-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4725619A (en) * 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB2216515A (en) * 1988-03-04 1989-10-11 Nippon Shinyaku Co Ltd Acylphenol derivatives
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
EP0625162B1 (de) * 1991-12-30 1998-05-13 Neurex Corporation Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
GB9306899D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5482964A (en) * 1994-10-11 1996-01-09 Warner-Lambert Company Substituted phenoxyhydroxypropyl amines as central nervous system agents
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
KR0147963B1 (ko) * 1995-01-10 1998-08-17 강박광 엔-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
GB9500691D0 (en) * 1995-01-13 1995-03-08 Smithkline Beecham Plc Compounds
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
US5741818A (en) * 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
US5688830A (en) * 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
AU4078897A (en) * 1996-08-23 1998-03-06 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6207685B1 (en) * 1996-12-06 2001-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Therapeutic application of a thienycyclohexylamine derivative
AU7698998A (en) * 1997-05-30 1998-12-30 Neurex Corporation Substituted peptidylamine calcium channel blockers
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
IT1295423B1 (it) * 1997-10-10 1999-05-12 Medivis S R L Uso della flunarizina nella terapia topica del glaucoma
CA2310664C (en) * 1997-11-21 2008-03-11 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9727521D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
US5905069A (en) * 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
WO1999055688A1 (en) * 1998-04-27 1999-11-04 Warner-Lambert Company Substituted diarylalkyl amides as calcium channel antagonists
SE9801494D0 (sv) * 1998-04-28 1998-04-28 Astra Pharma Prod Novel use
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
NZ508490A (en) * 1998-07-09 2003-08-29 Warner Lambert Co Use of a combination of a GABA analog and caffeine as an analgesic
US6316440B1 (en) * 1998-07-30 2001-11-13 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
JP2003506388A (ja) * 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
US6472530B1 (en) * 1999-09-22 2002-10-29 Ortho-Mcneil Pharmaceutical, Inc. Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6420383B1 (en) * 2000-03-23 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Thiepino[3,2-b]dihydropyridines and related compositions and methods
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
MXPA04002009A (es) * 2001-09-03 2004-07-08 Newron Pharm Spa Composicion farmaceutica que comprende gabapentina o un analogo de la misma y alfa-aminoamida y su uso como analgesico.
ATE359783T1 (de) * 2001-12-27 2007-05-15 Ortho Mcneil Pharm Inc Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
EP1438956A1 (de) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-Aminoamidderivate die als Antimigränemittel nützlich sind
EP1589959A2 (de) * 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Verfahren zur behandlung von erkrankungen der unteren harnwege mit natriumkanalmodulatoren
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CA2536764C (en) * 2003-08-25 2013-09-17 Newron Pharmaceuticals, S.P.A. .alpha.-aminoamide derivatives useful as anti-inflammatory agents
EP1535908A1 (de) * 2003-11-24 2005-06-01 Newron Pharmaceuticals S.p.A. N-Acyl-N'-Beznylalyklendiamin Derivate
EP1557166A1 (de) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamidderivate für die Behandlung von Funktionsstörungen der niedrigen Harnwege
EP1588704A1 (de) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidderivate zur Behandlung des Restless-Leg-Syndroms und der Suchterkrankungen
KR101277520B1 (ko) * 2004-09-10 2013-06-21 뉴론 파마슈티칼즈 에스. 피. 에이. （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물

Also Published As

Publication number Publication date
IL181445A0 (en) 2007-07-04
PL1809271T3 (pl) 2010-10-29
JP5319920B2 (ja) 2013-10-16
WO2006027052A3 (en) 2006-05-26
AU2005282028B2 (en) 2011-03-24
AR050638A1 (es) 2006-11-08
DK1809271T3 (da) 2010-09-20
PT1809271E (pt) 2010-08-30
DE602005021907D1 (de) 2010-07-29
HK1105359A1 (en) 2008-02-15
EP1809271B1 (de) 2010-06-16
JP2008512405A (ja) 2008-04-24
ME01801B (me) 2011-02-28
US20080096965A1 (en) 2008-04-24
HRP20100400T1 (hr) 2010-09-30
ES2347581T3 (es) 2010-11-02
TW200612894A (en) 2006-05-01
AU2005282028A2 (en) 2006-03-16
US20110184068A1 (en) 2011-07-28
NZ553970A (en) 2010-01-29
DK1809271T5 (da) 2010-12-06
AU2005282028A1 (en) 2006-03-16
CY1110770T1 (el) 2015-06-10
KR20070061863A (ko) 2007-06-14
CN101018546B (zh) 2013-06-12
WO2006027052A2 (en) 2006-03-16
RS51411B (en) 2011-02-28
NO20071792L (no) 2007-06-11
TWI351950B (en) 2011-11-11
BRPI0515154A (pt) 2008-07-08
EP1809271B9 (de) 2010-09-22
SI1809271T1 (sl) 2010-10-29
MX2007002713A (es) 2007-05-23
CA2577408C (en) 2013-07-09
CN101018546A (zh) 2007-08-15
NO338713B1 (no) 2016-10-03
RU2391973C2 (ru) 2010-06-20
EP1809271A2 (de) 2007-07-25
RU2007113190A (ru) 2008-10-27
KR101277520B1 (ko) 2013-06-21
IL181445A (en) 2014-03-31
CA2577408A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
ATE471147T1 (de) Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
ATE391718T1 (de) Phenylacetamide und ihre verwendung als glukokinase-modulatoren
DE602005027308D1 (de) Stabile salze von olanzapin
DK1830869T3 (da) Fremgangsmåde til behandling eller profylakse
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
DE112005002146A5 (de) Kanalsimulations- sowie Entwicklungsplattform und Verwendung derselben
DE502005007692D1 (de) Leuchte zur Ausleuchtung von Gebäudeflächen oder Gebäudeteilflächen
DE602004020156D1 (de) Verwaltung von Rahmenbursts
DE602005011285D1 (de) Formmasse von polymer
DE602005021091D1 (de) Eigenschaften saugfähiger kleidungsstücke zur eliminierung von regeldifferenz
DE602006004463D1 (de) Kristallform von asenapinmaleat
ATE512141T1 (de) Verwendung von tetrahydrobenzoxazinen als antioxidantien
DE602004005642D1 (de) Sicherheitssteuerung zur Durchführung von Standard- und Sicherheitssteuerungsprogrammen
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
DK1723135T3 (da) Kendte hydroxy-6-heteroarylphenanthridiner og deres anvendelse som pde4-inhibitorer
ATE411992T1 (de) Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
HK1124324A1 (en) 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
ATE510556T1 (de) Verwendung von erythropoietin
DE60335018D1 (de) Mittel zur verhinderung von hautalterung
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
DE50313495D1 (de) Abstandhalter für scheiben von mehrfachisoliergläsern
ATE483699T1 (de) Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
ATE457168T1 (de) Transdermales therapeutisches system von gestoden
ATE498326T1 (de) Anlage zur konzentration von tomatensaft
DK1581307T3 (da) Irs modulatorer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1809271

Country of ref document: EP